Interaction between COMT haplotypes and cannabis in schizophrenia: A case-only study in two samples from Spain

Schizophrenia Research

Volumn 127, Issue 1-3, 2011, Pages 22-27

  Costas, Javier ^a   Sanjuán, Julio ^b   Ramos Ríos, Ramón ^a   Paz, Eduardo ^a   Agra, Santiago ^a   Tolosa, Amparo ^b   Páramo, Mario ^a   Brenlla, Julio ^a   Arrojo, Manuel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cannabis; COMT; Gene environment interaction; Met158Val; Psychosis; Schizophrenia

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE;

ADULT; ARTICLE; CANNABIS SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MARIJUANA SMOKING; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SPAIN; VALINE;

EID: 79952312080     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2011.01.014     Document Type: Article

References (52)

1. Abramson J.H. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol. Perspect. Innov. 2004, 1:6.
2. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 2004, 184:110-117.
3. Belsky J., Jonassaint C., Pluess M., Stanton M., Brummett B., Williams R. Vulnerability genes or plasticity genes?. Mol. Psychiatry 2009, 14:746-754.
4. Bertolino A., Di Giorgio A., Blasi G., Sambataro F., Caforio G., Sinibaldi L., Latorre V., Rampino A., Taurisano P., Fazio L., Romano R., Douzgou S., Popolizio T., Kolachana B., Nardini M., Weinberger D.R., Dallapiccola B. Epistasis between dopamine regulating genes identifies a nonlinear response of the human hippocampus during memory tasks. Biol. Psychiatry 2008, 64:226-234.
5. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., Nosarti C., O' Carroll C.M., Seal M., Allen P., Mehta M.A., Stone J.M., Tunstall N., Giampietro V., Kapur S., Murray R.M., Zuardi A.W., Crippa J.A., Atakan Z., McGuire P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
6. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
7. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
8. Clarke G.M., Cardon L.R. Aspects of observing and claiming allele flips in association studies. Genet. Epidemiol. 2010, 34:266-274.
9. Costas J., Sanjuán J., Ramos-Ríos R., Paz E., Agra S., Ivorra J.L., Páramo M., Brenlla J., Arrojo M. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis. J. Psychiatr. Res. 2011, 45:7-14.
10. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., Goldman D., Xu K., Shabalina S.A., Shagin D., Max M.B., Makarov S.S., Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 2005, 14:135-143.
11. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57:594-608.
12. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:413-431.
13. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 2003, 25:115-121.
14. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 2001, 98(12):6917-6922.
15. ElSohly M.A., Ross S.A., Mehmedic Z., Arafat R., Yi B., Banahan B.F. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J. Forensic Sci. 2000, 45:24-30.
16. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., Weinberger D.R. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 2003, 60:889-896.
17. Gosso M.F., de Geus E.J., Polderman T.J., Boomsma D.I., Heutink P., Posthuma D. Catechol O-methyl transferase and dopamine D2 receptor gene polymorphisms: evidence of positive heterosis and gene-gene interaction on working memory functioning. Eur. J. Hum. Genet. 2008, 16:1075-1082.
18. Hall W., Degenhardt L. Schizophrenia secondary to cannabis use. Secondary Schizophrenia 2010, 169-177. Cambridge University Press, Cambridge. P. Sachdev, M.S. Keshavan (Eds.).
19. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananás L., Drukker M., Ramaekers J.G., van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
20. Henquet C., Di Forti M., Morrison P., Kuepper R., Murray R.M. Gene-environment interplay between cannabis and psychosis. Schizophr. Bull. 2008, 34:1111-1121.
21. Houston J.E., Murphy J., Adamson G., Stringer M., Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr. Bull. 2008, 34:580-585.
22. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
23. Lichtenstein P., Yip B.H., Bjork C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
24. Lin P.I., Vance J.M., Pericak-Vance M.A., Martin E.R. No gene is an island: the flip-flop phenomenon. Am. J. Hum. Genet. 2007, 80:531-538.
25. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melén K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
26. Manuck S.B. The reaction norm in gene × environment interaction. Mol. Psychiatry 2010, 15:881-882.
27. Mier D., Kirsch P., Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 2010, 15:918-927.
28. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
29. Morgan C.J., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192:306-307.
30. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., Maixner W., Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
31. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., Dwyer S., Holmans P., Marchini J.L., Spencer C.C., Howie B., Leung H.T., Hartmann A.M., Möller H.J., Morris D.W., Shi Y., Feng G., Hoffmann P., Propping P., Vasilescu C., Maier W., Rietschel M., Zammit S., Schumacher J., Quinn E.M., Schulze T.G., Williams N.M., Giegling I., Iwata N., Ikeda M., Darvasi A., Shifman S., He L., Duan J., Sanders A.R., Levinson D.F., Gejman P.V., Cichon S., Nöthen M.M., Gill M., Corvin A., Rujescu D., Kirov G., Owen M.J., Buccola N.G., Mowry B.J., Freedman R., Amin F., Black D.W., Silverman J.M., Byerley W.F., Cloninger C.R. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 2008, 40:1053-1055. Molecular Genetics of Schizophrenia Collaboration.
32. Okochi T., Ikeda M., Kishi T., Kawashima K., Kinoshita Y., Kitajima T., Yamanouchi Y., Tomita M., Inada T., Ozaki N., Iwata N. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr. Res. 2009, 110:140-148.
33. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., Cannon M., Karayiorgou M., Gogos J.A., Cotter D.R., Waddington J.L. Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
34. Piegorsch W.W., Weinberg C.R., Taylor J.A. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat. Med. 1994, 13:153-162.
35. Pitts J.E., Neal J.D., Gough T.A. Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J. Pharm. Pharmacol. 1992, 44:947-951.
36. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 2008, 53:90-94.
37. Prata D.P., Mechelli A., Fu C.H., Picchioni M., Kane F., Kalidindi S., McDonald C., Howes O., Kravariti E., Demjaha A., Toulopoulou T., Diforti M., Murray R.M., Collier D.A., McGuire P.K. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biol. Psychiatry 2009, 65:473-480.
38. Prata D.P., Mechelli A., Fu C.H., Picchioni M., Toulopoulou T., Bramon E., Walshe M., Murray R.M., Collier D.A., McGuire P. Epistasis between the DAT 3Δ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc. Natl Acad. Sci. USA 2009, 106:13600-13605.
39. Reuter M., Peters K., Schroeter K., Koebke W., Lenardon D., Bloch B., Hennig J. The influence of the dopaminergic system on cognitive functioning: a molecular genetic approach. Behav. Brain Res. 2005, 164:93-99.
40. Roffman J.L., Weiss A.P., Deckersbach T., Freudenreich O., Henderson D.C., Wong D.H., Halsted C.H., Goff D.C. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:990-995.
41. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Børglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Böttcher Y., Olesen J., Breuer R., Möller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Réthelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jönsson E.G., Terenius L., Agartz I., Petursson H., Nöthen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747. Genetic Risk and Outcome in Psychosis (GROUP).
42. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
43. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
44. Tan H.Y., Chen Q., Sust S., Buckholtz J.W., Meyers J.D., Egan M.F., Mattay V.S., Meyer-Lindenberg A., Weinberger D.R., Callicott J.H. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc. Natl Acad. Sci. USA 2007, 104:12536-12541.
45. Thaker G.K., Wonodi I., Avila M.T., Hong L.E., Stine O.C. Catechol-O-methyltransferase polymorphism and eye tracking in schizophrenia: a preliminary report. Am. J. Psychiatry 2004, 161:2320-2322.
46. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 2006, 60:141-151.
47. van Winkel R., Henquet C., Rosa A., Papiol S., Fananás L., De Hert M., Peuskens J., van Os J., Myin-Germeys I. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:10-17.
48. Xu H., Kellendonk C.B., Simpson E.H., Keilp J.G., Bruder G.E., Polan H.J., Kandel E.R., Gilliam T.C. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr. Res. 2007, 90:104-107.
49. Yang Q., Khoury M.J., Flanders W.D. Sample size requirements in case-only designs to detect gene-environment interaction. Am. J. Epidemiol. 1997, 146:713-720.
50. Zammit S., Spurlock G., Williams H., Norton H., Williams N., O'Donnovan M.C., Owen M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 2007, 191:402-407.
51. Zaykin D.V., Shibata K. Genetic flip-flop without an accompanying change in linkage disequilibrium. Am. J. Hum. Genet. 2008, 82:794-796.
52. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimarães F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.